Speakers

Expand/Collapse

Elaine Hamm
Chief Executive Officer
Ascend BioVentures & Otologic Pharmaceutics

Day Two

Thursday – May 27, 2021

2:40 pm | Discussion/Q&A

2:15 pm | Challenges of Early-Stage Investment

Jonas Dyhrfjeld-Johnsen
Chief Development Officer
Acousia Therapeutics

Day One

Wednesday – May 26, 2021

11:55 am | Discussion/Q&A

11:15 am | Translational Survival Challenges of Inner Ear Drug Development

9:00 am | Panel Discussion: Advancing Inner Ear Therapeutics Towards Industrial Success

Manny Simons
President, Chief Executive Officer & Co-Founder
Akouos

Day One

Wednesday – May 26, 2021

2:40 pm | Discussion/Q&A

1:50 pm | Precision Genetic Medicines for Inner Ear Disorders

9:00 am | Panel Discussion: Advancing Inner Ear Therapeutics Towards Industrial Success

Chieri Hayashi
Medical Director
Astellas

Day Two

Thursday – May 27, 2021

9:25 am | Sharing Astellas’ Approach to Otology: Challenges & Opportunities

10:30 am | Discussion/Q&A

Reimar Schlingensiepen
Chief Executive Officer
AudioCure Pharma

Day One

Wednesday – May 26, 2021

11:55 am | Discussion/Q&A

10:50 am | AC102 vs Standard of Care in Acute Hearing Loss

Michael Franti
Director & Head of Regenerative Medicine
Boehringer Ingelheim

Day One

Wednesday – May 26, 2021

4:55 pm | Discussion/Q&A

4:05 pm | Strategy to Trigger Hair Cell Regeneration and Ultimately Restore Hearing Function

Laurence Reid
Chief Executive Officer
Decibel Therapeutics

Day One

Wednesday – May 26, 2021

9:00 am | Panel Discussion: Advancing Inner Ear Therapeutics Towards Industrial Success

Jonathon Whitton
Vice President of Clinical Research
Decibel Therapeutics

Day One

Wednesday – May 26, 2021

2:40 pm | Discussion/Q&A

1:00 pm | Development of an AAV-Based Gene Therapy for Children With Congenital Hearing Loss Due to Otoferlin Deficiency (DB-OTO)

Abraham Scaria
Chief Scientific Officer
Iveric Bio

David Bredt
Executive Partner
MPM Capital

Day One

Wednesday – May 26, 2021

9:00 am | Panel Discussion: Advancing Inner Ear Therapeutics Towards Industrial Success

Day Two

Thursday – May 27, 2021

10:30 am | Discussion/Q&A

9:00 am | Targeting the α9α10 Nicotinic Acetylcholine Receptor for Hearing Loss

Beverley Isherwood
Programme Manager
Medicines Discovery Catapult

Vince Groppi
Chief Executive Officer
Oricula Therapeutics

Day Two

Thursday – May 27, 2021

10:30 am | Discussion/Q&A

9:50 am | ORC-13661 is Novel, First in Class Drug to Prevent Aminoglycoside-Induced Hearing Loss

Alan Foster
Vice President of Research
Otonomy

Day Two

Thursday – May 27, 2021

12:50 pm | Discussion/Q&A

12:25 pm | Optimizing Clinical Outcomes Through an Effective Drug Delivery Approach

David Weber
President & Chief Executive Officer
Otonomy

Day One

Wednesday – May 26, 2021

9:00 am | Panel Discussion: Advancing Inner Ear Therapeutics Towards Industrial Success

Stephen Huhn
Chief Medical Officer & Senior Vice President of Clinical Development
Pipeline Therapeutics

Day Two

Thursday – May 27, 2021

12:50 pm | Discussion/Q&A

12:00 pm | Early Clinical Trial Design Considerations in Hearing Restoration

Jim Ayala
Founder & Chief Executive Officer
Rescue Hearing

Day Two

Thursday – May 27, 2021

2:40 pm | Discussion/Q&A

2:00 pm | Developing a Gene Therapy from Bench to Clinic – On a Budget

Marcelo Rivolta
Chief Scientific Officer
Rinri Therapeutics

Day One

Wednesday – May 26, 2021

4:55 pm | Discussion/Q&A

4:30 pm | Development of First-in-Class Cell Therapy for Hearing Loss

Ralph Holme
Executive Director of Research
RNID

Geraldine Honnet
Chief Medical Officer
Sensorion

Day Two

Thursday – May 27, 2021

12:50 pm | Discussion/Q&A

11:35 am | Bringing a New Small Molecule to Patients for Sudden Sensorineural Hearing Loss (SSNHL) Disease

Karen Avraham
Vice Dean & Professor
Tel Aviv University

Day One

Wednesday – May 26, 2021

2:40 pm | Discussion/Q&A

1:25 pm | Gene Discovery & Therapy for Hearing Loss

Barbara Vona
Junior Group Leader
University of Tübingen

Day One

Wednesday – May 26, 2021

2:40 pm | Discussion/Q&A

2:15 pm | Advances in Hearing Loss Diagnostic Testing: A Gateway to Therapeutic Development

Anne Schilder
Chief Scientific Adviser
ENT Clinical

Day One

Wednesday – May 26, 2021

11:55 am | Discussion/Q&A

David Lucchino
Co-Founder, President & Chief Executive Officer
Frequency Therapeutics

Day One

Wednesday – May 26, 2021

9:00 am | Panel Discussion: Advancing Inner Ear Therapeutics Towards Industrial Success

Celia Belline
CEO & Co-founder
CILcare

Day Two

Thursday – May 27, 2021

10:15 am | Expanding Drug Portfolio in Hearing, with Fast-Track Development Strategies

10:30 am | Discussion/Q&A

Nishchay Mehta
Associate Professor - UCL
Scientific consultant - ENT Clinical

Day One

Wednesday – May 26, 2021

11:40 am | Data Science: In Search of the Deeper Structure of Hearing

11:55 am | Discussion/Q&A